Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to confirm the efficacy and safety of BaofeiKang Granule in the treatment of Combined Pulmonary Fibrosis and Emphysema patients.


Clinical Trial Description

A randomized, double blinded, placebo controlled study is conducted to observe the efficacy and safety of BaoFeiKang Granule in the treatment of patients with Combined Pulmonary Fibrosis and Emphysema. The Traditional Chinese Medicine(TCM) syndrome intergal,lung function ,Chronic Obstructive Pulmonary Disease Assessment Test(CAT)score, acute exacerbation, arterial blood gas analysis, chest High Resolution Computerized Tomography (HRCT)and liver and kidney function are to be calculated and tested before and after the trial.

1. Randomization All the selected cases is divided into the experimental group and the control group randomly, and the section size is 6. STATISTICAL ANALYSIS SYSTEM(SAS)statistical software are randomly assigned table,and clinical researchers given the corresponding code number to the selected qualified patients.According to the code number,patients receive the corresponding code number box.The persons who generate and preserve of tables are not involved in clinical trials.

2. Drug coding According to the protocol,the experimental duration of treatment is 3 months.The patients accept the medication for each month.

3. Blind method In the course of the study, the researchers and the subjects were not aware of the grouping of the research objects.

4. Sample size According to the formula,n=(Uα+Uβ)2*2P(1-P)/(P1-P0),the required sample size of each group is calculated.P1 represents for the efficiency of treatment group, P0 for the control group, P= (P1+P0) /2 * 100%;α=0.05,β=0.10,Uα=1.65,Uβ=1.28.According to the previous research results and literature research,P1=70%,P0=40%.It is calculated n = 47,and considering shedding rate of 20%,n =56.So actual each group includes 60 patients.

5. Implementation and management (1) training of 4 clinical researchers to master case collection methods and evaluation methods to minimize selection bias; (2) all experimental drugs are used in the same batch of drugs. (3) to collect data of the combination of medication and the treatment to exclude the impact of the above interference; (4) inform patients to get a more comprehensive evaluation and follow-up treatment.Special problems can get all respiratory department doctor's consultation, so as to achieve patient cooperation and understanding.(5)List the cases of loss or withdrawal, and specify the details and reasons. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02805699
Study type Interventional
Source Beijing Municipal Science & Technology Commission
Contact hongsheng Cui, Ph.D,Professor
Phone 010-54075410
Email hshcui@sina.com
Status Recruiting
Phase Phase 2
Start date June 2016
Completion date September 2019

See also
  Status Clinical Trial Phase
Terminated NCT02633293 - An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE Phase 2/Phase 3
Completed NCT02630316 - Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE Phase 2/Phase 3
Available NCT05572996 - Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease